Bibliographic record
Abstract
INTRODUCTION in Paris ... chestnuts in blossom ... holiday tables under the sun ... or so the song goes. But on that cold, rainy April evening, it was just plain miserable. That would also accurately describe the mood of John Williams, an American expatriate who had been living and working in Paris for just over three months. He still struggled with the language and the unfathomable bureaucracy. Worse yet, he was totally frustrated by his lack of ability to make anything positive happen at work. As he walked along the Seine on his way home from a disastrous few days at the office, he wondered how he was ever going to get the cooperation and commitment he needed to successfully market Gene Life's latest product. Gene Life Corporation It was only a short time ago that a group of genetic scientists from the Boston area formed a privately held company to focus on medical applications of genetic sequencing. All of the company founders were research physicians who had been associated with large universities in and around Boston. Since most of the founders were preeminent in their fields, obtaining venture capital was not difficult. The group was particularly interested in developing a genetic test for type II diabetes. This interest was based not only on their expertise but also the results of market surveys sponsored by the American Medical Association. It was clear that physicians were extremely interested in purchasing a potential test that could help in the diagnosis of type II diabetes. But, there was a limit on how much they were willing to pay. Unfortunately, Gene Life's first iteration of a user-friendly test kit could not be sold for any less than $3,500. Given the feedback from early marking attempts, physicians and hospitals considered the cost prohibitive. A year later, the research team discovered an innovative method to produce a test kit that could be sold to for around $500. After extensive testing, which produced very accurate diagnostic results, Gene Life started marketing the kit to physicians and hospitals in the United States. It was an immediate success, and the former small research company was immediately thrust into the competitive world of pharmaceutical manufacturing, marketing and sales. They brought in state of the art manufacturing specialists, built an extremely efficient manufacturing facility to keep costs low. This supported their cost leader marketing strategy and discouraged competition. The venture capital partner conducted an extensive marketing survey and concluded that it was in the best interest of all parties to take the company public. The IPO was managed by the Bank of Boston and resulted in $52 million in new equity ownership capital. Gene Life could now afford to bring their product to the international market. John Williams' Background Because of his unusual background, John Williams was brought in to Gene Life shortly after its inception. Right after high school, John decided not to go to college but rather worked for a construction company that immediately sent him to rural Quebec to build oil pipe lines. He eventually attained the position of crew chief where he managed up to thirty French-speaking Canadians as well as Polish-immigrant workers. However, he wanted more out of life and returned to the U.S. to attend Boston University. After graduating with a degree in biochemistry, John took a job with a large pharmaceuticals company. Three years of tedious, slow moving research led him to the conclusion that he was really more interested in the business aspects of the industry than the science. Hence, he left the job and earned his MBA at Harvard University. Upon completion of his degree, he ran into one of his undergraduate professors at a coffee shop in Fanuli Hall. Dr. Morton, who was one of the founding members of Gene Life, talked extensively about the company, its product and its difficulty in finding a competent manager who both understood genetic science and had the ability to effectively manage people. …
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".